“PBI-4050, either used alone or in Combi-1, demonstrated very promising early indications of efficacy, considering that current drugs approved for IPF only slow (but do not reverse) the decline in lung respiratory function”, said John Moran, Prometic’s chief medical officer.
“It is also important to note that during our clinical trial, there were no deaths nor did we see any subjects experiencing a decrease in FVC [how much someone can exhale] of 10% or more, contrary to the outcomes in the other IPF trials.”
In addition to demonstrating that the drug was safe and very well tolerated, an endpoint for the trial was to show there was benefit from its prescription either alone or in combination with nintedanib or pirfenidone, the drugs currently prescribed for IPF.
Pierre Laurin, ProMetic’s chief executive, added the results supported the rationale and clinical study design for the Phase 2/3 IPF clinical trial due to start in the second quarter.
“We expect to see PBI-4050, alone or in combination with one of the commercially approved IPF drugs, continue to outperform the current drugs in terms of efficacy, safety and tolerability”.
Story by ProactiveInvestors